All In Biotech

Drug Trial Radar · NCT00192452

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of MEDI-507, a Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Intravenous Infusion to Adults With Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Oct 25, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Mar 2001

Primary completion

Not stated

Study completion Dec 2001

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 19, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

\- The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8 infusions.

Conditions

  • Psoriasis

Interventions

  • MEDI-507Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Analyses of categorical data will be performed and analysis of continuous data will be performed using a one-way analysis of variance (ANOVA) with traetment group as a factor.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • MDS Pharma Services (US) Inc.

    Phoenix, Arizona

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • Northwest Kinetics

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.